FDA: Fresenius Kabi Issues Nationwide Recall of Tyenne® (Tocilizumab-aazg) Injection 400mg/20mL Vials Due to Presence of Glass
Published: 08/12/2026
Sources:
- Food and Drug Administration
Relevant To:
- Rural Emergency Hospitals,
- Assisted Living,
- Medical Office,
- Critical Access Hospitals,
- Home Health,
- Hospitals,
- Long Term Care,
- Ambulatory Care,
- Pharmacy,
- Rural Health Clinics
Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles.
- Tyenne® (tocilizumab-aazg) Injection is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (D…